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Chordomas are radio- and chemo-resistant tumours and metastasise in as many as 40% of patients. The aim of this study was to
identify potential molecular targets for the treatment of chordoma. In view of the reported association of chordoma and tuberous
sclerosis complex syndrome, and the available therapeutic agents against molecules in the PI3K/AKT/TSC1/TSC2/mTOR pathway, a
tissue microarray of 50 chordoma cases was analysed for expression of active molecules involved in this signalling pathway by
immunohistochemistry and a selected number by western blot analysis. Chordomas were positive for p-AKT (92%), p-TSC2 (96%),
p-mTOR (27%), total mTOR (75%), p-p70S6K (62%), p-RPS6 (22%), p-4E-BP1 (96%) and eIF-4E (98%). Phosphatase and tensin
homologue deleted on chromosome 10 expression was lost in 16% of cases. Mutations failed to be identified in PI3KCA and RHEB1
in the 23 cases for which genomic DNA was available. Fluorescence in situ hybridisation analysis for mTOR and RPS6 loci showed that
11 of 33 and 21 of 44 tumours had loss of one copy of the respective genes, results which correlated with the loss of the relevant
total proteins. Fluorescence in situ hybridisation analysis for loci containing TSC1 and TSC2 revealed that all cases analysed harboured
two copies of the respective genes. On the basis of p-mTOR and or p-p70S6K expression there is evidence indicating that 65% of
the chordomas studied may be responsive to mTOR inhibitors, rapamycin or its analogues, and that patients may benefit from
combined therapy including drugs that inhibit AKT.
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Chordoma is a rare malignant locally destructive tumour with a
characteristic morphology and immunohistochemical profile
(cytokeratin 19 and brachyury positive) that occurs, in the
majority of cases, in vertebral bones and presents mostly with a
large mass making wide excision rarely possible. Recurrent disease
is a common event and metastases occur in as many as 40% of
cases (Henderson et al, 2005; Romeo and Hogendoorn, 2006;
Vujovic et al, 2006; Tirabosco et al, 2008; Hallor et al, 2008).
Surgery, often ablative, is the main treatment option as the
tumours are largely resistant to chemotherapy and radiotherapy,
although proton/photon-beam radiotherapy is recommended for
local control if available (Park et al, 2006) (for review see Casali
et al, 2007).
Little is known about the genetic events that account for the
development and progression of chordoma although there are
reports that this tumour has developed in five patients with
tuberous sclerosis complex. This is a tumour suppressor gene-
related syndrome occurring on a background of germline
mutations in TSC1 and TSC2 (encoding hamartin and tuberin,
respectively). One of the cases harbouring a TSC2 mutation had a
clear loss of heterozygosity of the wild-type allele. The second case
with a TSC1 mutation revealed a reduced signal corresponding
to the wild-type allele (allelic imbalance), and this was interpreted
as loss of heterozygosity (Lee-Jones et al, 2004). Inactivation of
TSC1/TSC2 function results in the phosphorylation of mTOR and
its downstream effector molecules, the end result of which is
initiation of translation, cell growth and proliferation (for review
see Rowinsky (2004); MacKenzie and von Mehren (2007)).
Inhibitors to mTOR are available and therefore the possibility
exists of directed therapy for chordomas. mTOR exists in two
molecular complexes, (mTOR complex mTORC1 and mTORC2),
which exhibit different sensitivities to rapamycin and its analogues
(Kim et al, 2002; Sarbassov et al, 2004; Yang et al, 2006b).
However, investigation into mTOR activity in chordomas is
required before offering such treatments as evidence also exists
that the locus harbouring mTOR in chordomas is a region where
there is frequent genomic loss (frequency of 0.57) (Scheil et al,
2001; Hallor et al, 2008).
The regulation of mTOR is complex, but in summary, AKT, a
serine–threonine kinase, can be activated through a number of
mechanisms, including the binding of a variety of growth factors to Revised 25 February 2009; accepted 10 March 2009
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styrosine kinase receptors, resulting in the phosphorylation of PI3K
and PDK1 and subsequent inactivation of TSC1/TSC2 function,
through phosphorylation of TSC2 at threonine 1462 by AKT.
AKT can also be activated by RAS through PI3K, and through
the assembled downstream TORC2 (Downward, 2004; Yang et al,
2006a), and activation of the RAS/MEK/ERK signalling
cascade also induces tuberin phosphorylation independently
of AKT (Roux et al, 2004). Inactivation of TSC2 releases a negative
control on mTOR through the disinhibition of Rheb (RAS
homologue enriched in brain), a small GTPase, and brings
about phosphorylation of p70S6kinase (p70S6K) and 4E binding
protein-1 (4E-BP1), and downstream phosphorylation of S6
ribosomal protein (RPS6) and eukaryotic translation initiation
factor 4E (eIF-4E), respectively (Martin and Hall, 2005; Tee et al,
2005). Finally, activation of mTORC1 is also mediated by nutrients
and branched amino acids, in particular (Wullschleger et al, 2006).
This study focuses on determining if there is evidence for the
activation of PI3K/AKT/TSC1/TSC2/mTOR signalling in chordo-
mas in view of existing therapeutic inhibitors.
MATERIALS AND METHODS
Clinical samples
This study complies with Central Office for Research Ethics
Committees standards. The material, snap-frozen and paraffin-
embedded tissue, was obtained from the histopathology depart-
ment of The Royal National Orthopaedic Hospital. The clinical
data were retrieved from the clinical notes. The cohort studied
consisted of chordomas from 50 patients, 31 males and 19 females,
with a median age of 65 years (range 19–84). The tumours
were characterised by typical chordoma morphology and the co-
expression of a pan-cytokeratin, cytokeratin 19 and brachyury.
The sites of the tumours were sacrococygeal (n¼41), lumbar
(n¼6) and cervical (n¼3). In a period of follow-up ranging
from 6 to 120 months, 46% of patients had one local recurrence,
12% had two and the remainder had no recurrences. Metastases
involving bone, skin and lung occurred in 22% of patients. Frozen
tumour was available from 23 primary tumours and paraffin
embedded from all 50 cases (metastatic disease was not included).
Five of the tumours had a dedifferentiated component but this
material was only available from two cases and therefore the
dedifferentiated component was not studied.
Tissue microarray
The pathology was reviewed by AMF, AS and RT. A tissue
microarray (TMA) of all 50 chordomas was constructed using a
manual tissue arrayer (Beecher Instruments Inc., Sun Prairie, WI,
USA). At least two representative 0.6mm cores from each case
were taken for the array. An additional 120 cores were used as
control material and orientation markers and included human
salivary gland, kidney, thyroid, tonsil, lymph node, placenta, testis,
GIST, thyroid, renal cell and breast carcinomas.
Antibodies and analysis of immunohistochemistry
Details of the antibodies used and conditions for the immuno-
histochemistry (IHC) are presented in Table 1. The IHC was
performed either with the Ventana NexES Autostainer (Ventana
Medical Systems, Strasbourg, France), Bond maX Immunostainer
(Vision Biosystems, Newcastle upon Tyne, UK) or manually with
ventana reagents. Diaminobenzidine was the chromogen in all
reactions. Incubation without a primary antibody, as well as
incubation with the matching IgG isotype control, under the same
conditions for each antibody, served as negative controls.
Each antibody was scored with reference to a positive internal
control on the TMA. The scoring system employed was as follows:
negative in the absence of immunoreactivity, ‘low’ when the
immunoreactivity was unequivocal but less strong than the
positive control and ‘high’ when the immunoreactivity was at
Table 1 Details of antibodies used for immunohistochemistry in this study
Antibody/clone Source Antigen retrieval Dilution
Incubation time
and temperature Method
Cytokeratin 19 clone b170 Novocastra, Peterborough, UK Protease, 20min 1:100 30min at 371C Ventana NexES autostainer
Brachyury Santa Cruz, CA, USA Pressure cooker, 2min 1:50 30min at 371C Ventana NexES autostainer
PTEN clone 28H6 Abcam, Cambridgeshire, UK Pressure cooker, 2min 1:100 30min at 371C Ventana NexES autostainer
CINtec p16
INK4a clone E6H4TM mtm laboratories AG,
Heidelberg, Germany
Dako ERS, 40min, Ely,
Cambridgeshire, UK
20min at 371C Bond maX immunostainer
p-AKT (ser 473) clone 736E11 Cell Signaling Technology,
Danvers, MA, USA
Pressure cooker, 6min 1:50 Overnight incubation
at 41C
Manually with Ventana
reagents
Harmatin/TSC1 Cell Signaling Technology Pressure cooker, 2min 1:25 30min at 371C Ventana NexES autostainer
Tuberin/TSC2 Santa Cruz Pressure cooker, 2min 1:100 30min at 371C Ventana NexES autostainer
p-Tuberin/TSC2 (Thr1462)
(clone ab59274
Abcam Pressure cooker, 4min 1:25 Overnight incubation
at 41C
Manually with Ventana
reagents
p-mTOR (ser 2448) clone 49F9 Cell Signaling Technology Pressure cooker, 3min 1:100 30min at 371C Ventana NexES autostainer
mTOR Cell Signaling Technology Pressure cooker, 4min 1:50 Overnight incubation
at 41C
Manually with Ventana
reagents
Phospho-p70 S6K1 (Thr 389) Cell Signaling Technology Pressure cooker, 4min 1:50 Overnight incubation
at 41C
Manually with Ventana
reagents
S6K Abcam Pressure cooker 6min 1:100 Overnight incubation
at 41C
Manually with Ventana
reagents
p-S6RP (ser235/236) clone 91B2 Cell Signaling Technology Pressure cooker, 3min 1:50 30min at 371C Ventana NexES autostainer
S6RP Cell Signaling Technology Pressure cooker, 2min 1:100 30min at 371C Ventana NexES autostainer
p-4EBP1 (Thr70) Cell Signaling Technology Pressure cooker, 2min 1:50 Overnight incubation
at 41C
Manually with Ventana
reagents
eIF-4E Cell Signaling Technology Pressure cooker, 2min 1:50 Overnight incubation
at 41C
Manually with Ventana
reagents
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sleast as strong as the positive control. The positive cases showed
immunoreactivity in more than 95% of the neoplastic cells. Non-
neoplastic cells (macrophages, lymphocytes and fibroblasts) in the
cores were used as internal negative controls.
Protein isolation and western blot analysis
Ten 10mm sections were cut from snap-frozen resected specimens.
Western blot analysis was carried out according to standard
methodology. Briefly, protein extracts (30mg) were fractionated by
SDS-8% polyacrylamide gel electrophoresis (unless otherwise
stated) and transferred to a PVDF Immobilion-P transfer
membrane (Millipore Corp., Bedford, MA, USA) by standard semi-
dry electrotransfer methods. The membrane was blocked with
blocking reagents (PBS, 0.1% Tween 20, 5% BSA) for a minimum
of 30min and probed with the appropriate primary antibody
overnight at 41C. Blots were washed in 1  PBS with 0.1%
Tween (PBS-T) and incubated for 1h at room temperature with
the appropriate secondary horseradish peroxidase-conjugated
antibody, and enhanced using chemiluminescence detection
(Amersham GE Healthcare, Buckinghamshire, UK).
The following antibodies were used for western blotting at
a dilution of 1:1000 with overnight incubation at 41C unless
otherwise stated: p-AKT (ser 473) (dilution 1:250; Cell Signaling
Technology, Danvers, MA, USA), total AKT (Cell Signaling
Technology), isoform 1 and 2 of p70S6K, which were kindly
provided by Professor Ivan Gout (University College London,
UK), p-4E-BP1 (Thr 70) (Cell Signaling Technology), p-RPS6
(ser235/236) (Cell Signaling Technology), p-p70S6K (Cell Signaling
Technology), S6 Ribosomal protein (clone 54D2; dilution Cell
Signaling Technology), mTOR (clone 7C10; Cell Signaling
Technology), GAPDH (Mab 6C5, dilution 1:5000, incubation
60min at room temperature; Advanced Immunochemical Inc.,
Long Beach, CA, USA). Hela cells were used as a positive control
when assessing for activation of PI3K/AKT/TSC1/TSC2/mTOR
molecules (data not shown).
Nucleic-acid isolation and mutational analysis by direct
sequencing
Sampled neoplasms used for nuclei acid extraction comprised
between 60 and 80% of tumour. PCR primers for each gene are
described in Supplementary Table 1. DNA was extracted using
proteinase K (Qiagen, Crawley, UK) from 23 frozen chordomas.
Fifty to 100ng of genomic DNA was amplified by the following
touchdown PCR protocol, with annealing temperature reduced by
11C per cycle from 651 to 561C followed by 35 further cycles at
561C as described above. The PCR was performed in a total volume
of 50ml containing 5mlo f1 0   Hotstart buffer I, 0.2mM of the
dNTP mix, 100pM of each primer, 1U of Hotstart DNA polymerase
(CLP, San Diego, CA, USA). PCR products were purified using
Qiagen purification PCR kit (Qiagen) and DNA sequencing was
performed at the Scientific Support Services, UCL. Sequencing
reactions were run using GenomeLab DTCS Quick Start chemistry
(Beckman Coulter (UK) Ltd Biomedical Research, Bucks, UK) and
were analysed on a CEQTM8000 Genetic Analysis System (Beck-
man Coulter).
RNA was extracted from paraffin-embedded samples using
Optimum FFPE RNA Isolation Kit (Ambion Europe, Huntington,
Cambridgeshire, UK) and from frozen tissue using TRIzol reagent
(Invitrogen Ltd, Paisley, Scotland, UK) followed by purification
with RNeasy columns with an additional on-column DNAse I
treatment (Qiagen) according to the manufacturer’s instructions to
avoid genomic DNA contamination. Approximately 150ng of the
total RNA extracted from each sample was reverse transcribed
using Superscript III First-Strand Synthesis kit (Invitrogen) accor-
ding to the manufacturer’s instructions and using gene-specific
primers for different exons to avoid amplification from gDNA
(Supplementary Table 1).
FISH analysis of TSC1, TSC2, mTOR and RPS6
Fluorescence in situ hybridisation (FISH) was performed on TMAs
using probes from the RP11 BACs library. RP11-81C14, RP11-
304L19, RP11-1107P2 and RP11-624N8 were used for assessing
TSC1, TSC2, mTOR and RPS6 allelic loss, respectively (BACPAC
Resources Center, Oakland, CA, USA). Centromeric probes, CEP9
and CEP16, were used to assess the presence of two copies of
chromosome 9 (RPS6) and 9 and 16 (TSC1 and TSC2, respectively)
(Vysis, Abbott Laboratories Inc., Des Plaines, IL, USA), and
a-satellite D1Z5 was used for chromosome 1 (mTOR). The probes
were prepared with reagents from Vysis. TMA sections were
de-paraffinised in xylene and dehydrated in ethanol. Sections were
pretreated using the Paraffin Pretreatment Reagent Kit II (Vysis):
the slides were placed in the pretreatment solution at 801C for
50–70min and in pepsin solution 0.05% at 371C for 20–25min.
The probe, applied to the slides, were co-denatured for 5min at
731C and hybridised for at least 16h at 371C in a Thermo-Brite
hybridiser (Iris, Westwood, MA, USA). The slides were washed in
formamide-free solutions: 2  SCC/0.3% NP40 (Igepal) at room
temperature for 5min, at 731C for 2min and at room temperature
for 1min, and then counterstained with DAPI and analysed under
a fluorescent microscope (Olympus, Watford, Hertfordshire, UK)
using AnalySIS software (Olympus). The chromosome localisation
of all BAC clones was confirmed on normal cells in metaphase.
Fifty non-overlapping nuclei that contained unequivocal signals
were counted for each case. Hemizygous deletion of RPS6 and
mTOR was defined as more than 20% of non-overlapping tumour
nuclei containing one RPS6 or mTOR locus red signal and by the
presence of two CEP9 and D1Z5 green signals for RPS6 and mTOR,
respectively.
RESULTS
Immunohistochemistry results
More than 90% of the chordomas expressed p-AKT (Ser243), p-
TSC2 (Thr1462), p-4E-BP1 (Thr70) and eIF-4E as assessed by IHC
(Figure 1, Table 2). The labelling pattern of these different
antibodies was largely similar and consisted of diffuse granular
cytoplasmic immunoreactivity, although nuclear positivity for
p-AKT and p-4E-BP1 was also noted in less than 10% of cases
(Figure 1). In contrast, phosphorylation of mTOR (Ser2448),
p70S6K (Thr389) and RPS6 (Ser235/236) was found in only 13 of
48 (27%), 29 of 46 (62%) and 11 of 49 (22%) cases, respectively
(Table 2, Figure 1, and Supplementary Table 2).
Correlation of immunohistochemistry and western blot
results
The western blot data on selected cases for p-AKT, p-4E-BP1 and
p-p70S6K were in complete concordance with the IHC results
(Figure 2). In addition to the phosphorylated status of p70S6K by
IHC, all six chordomas analysed by western blot were positive for
the rapamycin-sensitive S6K isoform 1, 70kDa (Figure 2). Western
blot analysis for p-mTOR confirmed the IHC data in four of six
cases, showing the presence of the activated protein in one case
and the absence in three cases.
The p-RPS6 IHC was confirmed in five of the six cases analysed
by western blotting: the one discrepant result showed that one
immunoreactive case was negative by western blot (Figure 2).
Western blot analysis revealed total RPS6 protein in all these six
cases although two of these were negative for total protein by IHC.
These two cases revealed loss of one RPS6 allele (vide infra), and
both were negative for p-RPS6 by western blot, suggesting that the
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Figure 1 Continued.
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spositive result for total RPS6 by western blot may be explained by
non-neoplastic stromal cells contaminating the protein lysate.
Correlation of mTOR-positive chordomas with other
markers
Of the 13 (27%) immunoreactive chordomas for p-mTOR, 12 were
immunoreactive for total mTOR protein and showed two copies of
the mTOR by FISH, where data were available, and all showed
phosphorylation of 4E-BP1 and expressed eIF-4E. Eleven of these
13 p-mTOR-positive cases showed activation of p-p70S6K, and
7 showed activation of p-RPS6. The two cases negative for
p-p70S6K activation were also negative for p-RPS6 (Table 2 and
Supplementary Table 2).
Correlation of mTOR-negative chordomas with other
markers
Thirty-five of 48 chordomas were negative for p-mTOR; 30 of
these could be analysed and 21 (70%) were immunoreactive for
total mTOR. As mTOR is found in a region reported to be
frequently lost in chordomas and other neoplasms, the tumours
were analysed for allelic loss by FISH (Figure 3). Of these 21 total
mTOR-positive cases, 11 showed two mTOR alleles and 4 revealed
loss of one allele (Figure 4A). This left 9 of 30 (30%) p-mTOR-
negative cases exhibiting no total mTOR protein as assessed
by IHC: five of these cases showed loss of one allele by FISH,
two cases showed two copies of the gene and there were no data
on two cases.
Approximately 50% of the p-mTOR-negative chordomas (16
of 33: 12 of which were immunoreactive for total mTOR)
showed activation of neither p70S6K nor RPS6. The remaining
17 p-mTOR-negative chordomas were positive for p-p70S6K, 9 of
15 (60%) of which were immunoreactive for total mTOR, but only
one of these cases was positive for RPS6 (Figure 4A).
Correlation of RPS6-negative chordomas with other
markers
Thirty-eight of 49 (78%) chordomas were negative for p-RPS6 and
22 of 35 analysable cases (no data for 3 cases of the 38) showed
no expression of the total protein RPS6. Fluorescence in situ
hybridisation data showed that 18 of the 20 (90%) analysable cases
(two had no FISH data available out of the 22) had only one copy
of the gene (Figure 4B). In total, 21 cases of 47 (47%) showed loss
of one copy by FISH (Supplementary Table 2) (Figure 3).
In view of RPS6 being located in the same chromosomal region
as CDKN2A (p16 (INK4)), a common tumour suppressor gene that
is lost frequently in chordomas (Hallor et al, 2008), we speculated
that the allelic loss of RPS6 correlated with the loss of CDKN2A.
This was confirmed by showing that CDKN2A was detected by IHC
in only 5 of 48 chordomas (Table 2) and that these 5 cases showed
no evidence of allelic loss for RPS6. Furthermore, total RPS6
protein was detected by IHC in four of these (no data for one case,
Supplementary Table 2). In contrast, 10 CDKN2A-negative cases
showed p-RPS6 positivity and 9 of these showed no RPS6 allelic
loss (no data for one case) (Supplementary Table 2).
FISH results for TSC1 and TSC2
Fluorescence in situ hybridisation for TSC1 (28 of 28 cases) and
TSC2 (24 of 24 cases) showed two alleles.
Phosphatase and tensin homologue deleted on
chromosome 10 in chordoma
Phosphatase and tensin homologue deleted on chromosome
10 (PTEN), a tumour suppressor gene, which when not expressed
contributes to constitutive phosphorylation of AKT and activation of
the downstream pathways, displayed no immunoreactivity in 16% of
chordomas (Figure 1, Table 1). The absence of PTEN by IHC was
confirmed by semi-quantitative RT-PCR (data not shown). The
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Figure 1 Transmitted light photomicrographs of chordoma characterised by cords and clusters of uniform cells with vacuolated cytoplasm set within a
myxoid stroma (Ai) and immunoreactive (nuclear) for brachyury (Aii) and cytokeratin 19 (Aiii). The photomicrographs on the left-hand panel represent
positive control tissues (breast carcinoma Bi, Ci, Di, Ei, Fi, Gi; colon Hi) that are immunoreactive for the indicated antibodies. The middle panel shows
representative chordomas, which were scored as ‘strong’ for expression of the indicated antibody, indicating that the immunoreactivity is as strong as that in
the positive control. The right-hand panel includes representative chordomas that were not immunoreactive for the relevant antibody. The bar¼50mm.
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sabsence of PTEN expression did not correlate with the presence of
metastatic disease, local recurrence or a dedifferentiated component.
Mutations in RHEB and PI3KCA are not detected in
chordomas
Direct sequencing for predicted mutations in RHEB codons 15, 16
and 64, which are similar to K-RAS codons 12, 13 and 61,
respectively (Li et al, 2004; Yan et al, 2006), and for common
mutations in PI3KCA (exons 4, 5, 7, 9 and 20), failed to reveal
mutations (Samuels et al, 2004) (see Supplementary Table 3).
DISCUSSION
mTOR, a protein kinase, is a pivotal regulator of protein synthesis
and controls entry into G1 phase of the cell cycle through
phosphorylation of the substrates p70S6K and 4E-BP1, molecules
that cooperate in translational initiation and ribosomal biogenesis.
It is for these reasons that mTOR inhibitors are considered
potential therapeutic agents in tumours where mTOR signalling is
activated. On the basis of this study of 50 chordomas, we consider
that there is evidence that 65% of the tumours are potentially
responsive to mTOR antagonists. This figure is generated by the
finding that 27% (n¼13) of the chordomas exhibit phospho-
rylated mTOR and a further 18 cases express p-p70S6K although
they are negative for p-mTOR.
p-p70S6K is generally used in preference to p-mTOR to assess
the tumour response to mTOR antagonists and to predict which
tumours may be responsive to such agents (for reviews see Boulay
et al (2004); MacKenzie and von Mehren (2007)). Indeed,
phosphorylated mTOR has been generally found to be expressed
in relatively low numbers of tumours, and several studies make no
reference to tumour mTOR expression when assessing the effect of
rapamycin and or its analogues (Jaeschke et al, 2002; Gao et al,
2003; Krishnan et al, 2006; El-Salem et al, 2007; Lu et al, 2008;
Table 2 Immunohistochemistry for the AKT/TSC/mTOR pathway molecules in chordomas
PTEN CDKN2A
p-AKT
(ser473) TSC1 TSC2
p-TSC2
(Thr1462)
p-mTOR
(ser2448) mTOR
p-S6K
(Thr389) S6K
p-RPS6
(ser235/
236) RPS6
p-4EBP1
(Thr70) eiF-4E
0 (no immuno-
reactivity)
7 46 4 26 0 2 35 11 18 0 41 23 2 1
Low immuno-
reactivity
28 2 31 14 40 47 5 33 11 50 8 21 25 35
High immuno-
reactivity
9 0 14 0 8 0 18 0 3 1 21 12
Positive cases/
total no.
37/43 2/48 45/49 14/40 40/40 47/49 13/48 33/44 29/47 50/50 11/49 22/45 46/48 47/48
% 86 4 92 35 100 96 27 75 62 100 22 49 96 98
Although the TMA was built with 50 chordomas, the total number described for each antibody represents the number that was possible to analyse. The scoring system
employed was as follows: negative in the absence of immunoreactivity, ‘low’ when the immunoreactivity was unequivocal but less strong than the positive control and ‘high’ when
the immunoreactivity was at least as strong as the positive control. In all of the positive cases, the immunoreactivity was present in more than 95% of the neoplastic cells.
AB Western blotting
Patient ID
p-AKT (ser473)
p-mTOR (ser2448)
p-p70S6K1 (Thr389)
Total p70S6K1
Total RPS6
p-RPS6 (Ser235/236)
p-4E-BP1 (Thr70)
GAPDH
Total mTOR
Total AKT
Chdm 6 Chdm 52 Chdm 88 Chdm74 Chdm 49 Chdm 51 Chdm 6
Low
ND
0
Low
Low
Low
Low
0
0
High
ND
0
Low
High
Low
High
0
Low
High
ND
High
Low
High
Low
High
High
High
High
ND
High
Low
High
Low
High
High
Low
High
ND
0
0
Low
Low
High
0
0
High
ND
High
Low
Low
Low
Low / 
equivocal
0
Low
Chdm 52 Chdm 88 Chdm74 Chdm 49 Chdm 51
Immunohistochemistry
Figure 2 Validation of the immunohistochemistry results by western blotting for selected targets in the PI3K/AKT/TSC1/TSC2/mTOR pathway on six
chordoma (Chdm) cases: (A) western blotting for p-AKT (ser473), total AKT, p-mTOR (ser2448), total mTOR, p-p70S6K (Thr389), isoform 1 of p70S6K,
p-RPS6 (ser235/236), total RPS6 and p-4E-BP1 (Thr70). The membranes were stripped and reprobed with anti-GAPDH antibody to assure even loading of
proteins in each lane. (B) IHC data for the samples analysed by western blot. Hela cells were used as a positive control when assessing for activation of PI3K/
AKT/TSC1/TSC2/mTOR molecules (data not shown).
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sScheper et al, 2008). Technical difficulties involved in detecting
large phosphorylated proteins (mTOR 289kDa) (Tkaczyk et al,
2002), in addition to the general transient expression of
phosphorylated proteins, may contribute to the difficulty in
detecting p-mTOR (Riemenschneider et al, 2006). mTOR phos-
phorylation may also occur on a variety of residues that we have
not tested (Cheng et al, 2004).
We consider that the 9 (20%) chordomas that do not express
mTOR (total and phosphorylated) protein as assessed by IHC
(five of these nine revealed only one mTOR allele (two cases
with both alleles, two cases no data)) are unlikely to respond to
mTOR inhibitors. Furthermore, we also speculate that the 10 cases
that express total mTOR but negative for p-mTOR, p-p70S6K
and p-RPS6 would also be at high risk of not responding to
mTOR antagonists. On the basis of this calculation, 35% of
our chordomas would be unlikely to be responsive to mTOR
antagonists.
The complete absence of mTOR expression in nine chordomas
raises the question as to how cells survive in the absence of
ribosomal biogenesis. One explanation is that the IHC for mTOR is
not sufficiently sensitive or that very low levels of mTOR are
required for assembling the protein complex (mTORC1). Alter-
natively, an mTOR-independent pathway, capable of bringing
about ribosomal biogenesis and initiation of translation, may be
activated. The report that RAS/MEK/ERK pathway activates RPS6
independently of mTOR through p90 ribosomal S6 kinase supports
this postulate (Roux et al, 2004).
In view of the importance of ribosomal synthesis in cell growth,
the absence of RPS6 protein expression in 58% of chordomas is
striking but appears to be a robust result because the IHC data are
supported by the finding of RPS6 allelic loss in 21 of the 23 cases.
Furthermore, the data correlate with the loss of CDKN2A that lies
on chr 9p21.3 and is located adjacent to the cytoband harbouring
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Figure 3 Photomicrographs of interphase fluorescent in situ hybridisa-
tion of chordomas showing an example of allelic loss (right-hand side
columns) and the normal two copies (left-hand side columns) for mTOR
(top row) and for RPS6 (bottom row). The red signals identify mTOR and
RPS6, respectively. The green signals represent chromosome 9 a-satellite
probe CEP9 for RPS6, and the D1Z5 a-satellite probe identifies the
chromosome 1 centromere for mTOR.
p-mTOR-negative cases N=35
p-S6K negative N=16/33 (49%) p-S6K positive N=17/33 (51%)
Total mTOR detected N=21/30 
(70%) 
No total mTOR detected N=9/30 
(30%) 
(Total mTOR detected N=12/16 (75%))
2 copies N=2/7 (29%) 
1 copy N=5/7 (71%)
No data N=2
2 copies N=11/15 (73%)
1 copy N=4/15 (27%)
No data N=6
No data N=5
p-RPS6 negative N=13/16 (81%) p-RPS6 positive N=1/17 (0.1%)
No data N=2 
(Total mTOR detected N=9/15 (60%)
No data N=2 
p-RPS6  positive N=11/49 (22%) p-RPS6 negative N=38/49 (78%)
Total RPS6 positive N=13/35 
(37%)
Total  RPS6 negative N=22/35 
(63%)
2 copies N=2/20 (10%)
1 copy N=18/20 (90%)
2 copies N=10/12 
(83%)
1 copy  N=2/12 (17%)
Total RPS6 negative  N=1/10 
(10%)
Total RPS6 positive N=9/10 
(90%)
No data N=3 
2 copies N=9/9 
(100%)
RPS6 N=49
No data N=1
IHC
FISH
1 copy N=1/1 (100%) No data N=1 No data N=2 
IHC
FISH
Figure 4 Schematic diagrams representing chordomas analysed for mTOR and p70S6K (A), and RPS6 (A and B) (total and activated forms) by
immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH).
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sRPS6 (chr 9p22.1). Hence, the lack of expression of RPS6
protein expression suggests that other p70S6K substrates, such
as splicing factor SCAR, translation initiation factor eIF-4B, EF-2B
kinase and pro-apoptotic protein Bad1 (Harada et al, 2001; Raught
et al, 2004; Richardson et al, 2004), which are less well studied, are
likely to undertake this important function (Ruvinsky and
Meyuhas, 2006).
It is not clear how loss of RPS6 contributes to the development
of neoplasia although its allelic loss has also been reported in
chondrosarcomas, a tumour with similarities to chordomas
(Rozeman et al, 2006). Interestingly, a causal relationship between
RPS6 phosphorylation and protein synthesis has revealed
conflicting results. In addition to reports of activation of this
protein resulting in elevated cell growth, there is also evidence of
increased global protein synthesis in embryonic fibroblasts derived
from rpS6
 /  mice compared with wild-type cells (Ruvinsky et al,
2005). Furthermore, germline mutations in RPS19, which occur
in patients with Blackfan–Diamond syndrome, a cancer suscep-
tibility syndrome associated with haematological malignancies,
have already established a role for the loss of RP in cancer.
Mutations in this syndrome are directly related to loss
of expression of RPs, such as (RP)S19, RPL5 and RPL11
(Draptchinskaia et al, 1999; Cmejla et al, 2009).
One of the reasons for embarking on the analysis of the mTOR
pathway in chordomas was the reported loss of heterozygosity in
chordomas in two individuals with tuberous sclerosis complex
syndrome (Lee-Jones et al, 2004). However, our finding that AKT
is activated in over 90% of chordomas argues that the tumour
suppressor genes, TSC2 and TSC1, in sporadic chordoma are likely
to be ‘inactivated’ not as a result of loss of heterozygosity but
rather by phosphorylation of TSC2, at threonine 1462, by p-AKT
(Inoki et al, 2002). Indeed, if the tumour suppressor genes were
inactivated, the absence of the TSC2 protein would be expected
and this was not the case.
The failure to detect RHEB and common PI3K mutations in 23
chordomas provides evidence that these genetic events are unlikely
to account for chordoma tumourigenesis in most cases. Further-
more, the published array CGH data showing that neither AKT nor
PI3KCA is amplified in 21 cases largely exclude activation of AKT
through these genetic events (Hallor et al, 2008). However, these
experiments are not exhaustive and additional analyses on greater
numbers of genes, in larger tumour series, are warranted.
Functional studies are required to validate our findings, but
accessing appropriate control material (notochord), the availabil-
ity of only one slow-growing chordoma cell line, UCH-1 (Scheil
et al, 2001), and the scarcity of animal models prevents this avenue
of investigation (although we established xenografts from five
different chordomas in nude mice, the tumours disappeared when
passaged into a second animal (data not shown)), making this
approach difficult. Nevertheless, our findings provide an evidence
base for treating selected chordomas with mTOR, AKT inhibitors
and antisense molecules to the attractive cancer target, eIF-4E
(Graff et al, 2008). A combination of agents, rather than individual
drugs, is more likely to offer therapeutic success particularly as
there is evidence that AKT is activated at ser473 by TORC2,
a rapamycin-insensitive molecule (Sarbassov et al, 2005).
The development of a new generation of mTOR-blocking
agents (TORKinibs) that interrupt the TORC2 complex is under
development and may provide therapeutic benefit over what is
currently available (Feldman et al, 2009).
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